No abstract

No abstract

No abstract

The low-intensity attack flows used by Crossfire attacks are hard to distinguish from legitimate flows. Traditional methods to identify the malicious flows in Crossfire attacks are rerouting, which is based on statistics. In these existing mechanisms, the identification of malicious flows depends on the IP address. However, the IP address is easy to be changed by attacks. Compared with the IP address, the certificate is more challenging to be tampered with or forged. Moreover, the traffic trend in the network is towards encryption. The certificates are popularly utilized by IoT devices for authentication in encryption protocols. DTLShps proposed a new way to verify certificates for resource-constrained IoT devices by using the SDN controller. Based on DTLShps, the SDN controller can collect statistics on certificates. In this paper, we propose Certrust, a framework based on the trust of certificates, to mitigate the Crossfire attack by using SDN for IoT. Our goal is threefold. First, the trust model is built based on the Bayesian trust system with the statistics on the participation of certificates in each Crossfire attack. Moreover, the forgetting curve is utilized instead of the traditional decay method in the Bayesian trust system for achieving a moderate decay rate. Second, for detecting the Crossfire attack accurately, a method based on graph connectivity is proposed. Third, several trust-based routing principles are proposed to mitigate the Crossfire attack. These principles can also encourage users to use certificates in communication. The performance evaluation shows that Certrust is more effective in mitigating the Crossfire attack than the traditional rerouting schemes. Moreover, our trust model has a more appropriate decay rate than the traditional methods.

Gonadotropin-releasing hormone agonist(GnRH-a) is generally added to improve pregnancy outcomes of adenomyosis based hormone replacement therapy cycle. Our objective in this study is to investigate whether adding GnRH-a can obtain better pregnancy outcomes. In this retrospective analysis, a total of 341 patients with adenomyosis complicated in vitro fertilization-embryo transfer(IVF-ET) of the frozen embryo transfer (FET). The control group was only treated by hormone replacement therapy cycles to prepare emdometrium, and the study group was added GnRH-a before using hormone to adjust menstruation period. Based on the similar baseline values and embryological data, there was no significantly difference about their clinical pregnancy rates (40.63% vs 42.54%, P=0.72) and live birth rates (23.75% vs 23.75%, P=0.74) between the control group and the study group. Other secondary outcomes including clinical miscarriage rates, ectopic pregnancy rates, preterm pregnancy rates and term pregnancy rates did not show significant difference between the two groups. Compared with using hormone replacement therapy cycle alone, GnRH-a down-regulation based on hormone replacement therapy cycle may not increase the rates of clinical pregnancy and live birth rates in IVF-ET of FET for infertile patients with adenomyosis.